Legal costs in the billions of dollars a year aren’t new for Johnson & Johnson, one of the world’s most sued companies. Ongoing talcum powder verdicts, combined with an industry-wide pricing controversy, may represent greater extra-legal risk in the form of negative public opinion that may influence policy proposals to reshape the industry.
In this research brief, we discuss:
- JNJ talcum powder controversy, as it moves from civil litigation to federal investigation.
- Rising drug prices, which are affecting a growing subsection of concerned Americans.
- Federal policy proposals that may threaten pharmaceutical companies’ revenues.
- Emerging beta factor for the pharmaceuticals industry.